Newscast – Page 98 – media

Phase III IMpower131 Study Showed Genentechs TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People with a Type of Advanced Squamous Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ® (atezolizumab) plus chemotherapy (carboplatin and ABRAXANE® [albumin-bound paclitaxel; nab-paclitaxel]) reduced the risk of disease worsening or death (progression-free survival; PFS) compared with chemotherapy alone in the initial (first-line) treatment of people with advanced squamous non-small cell lung cancer (NSCLC). Safety for the TECENTRIQ and chemotherapy combination appeared consistent with the known safety profile of the individual medicines, and no new safety signals were identified with the combination. At this interim analysis a statistically significant overall survival (OS) benefit was not observed and the study will continue as planned. These data will be presented at an upcoming oncology congress.
- Source: cleveland19
- 773
- March 22, 2018
Chemotherapy Clinical Trials Genentech NSCLC oncology
FDA expands approval of Adcetris for first-line treatment of Stage III or IV classical Hodgkin lymphoma in combination with chemotherapy

The U.S. Food and Drug Administration today approved Adcetris (brentuximab vedotin) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy.
- Source: finance.yahoo
- 625
- March 22, 2018
ADCETRIS cancer FDA Hodgkin lymphoma New Approvals
New wearable brain scanner allows patients to move freely for the first time

A new generation of brain scanner, that can be worn like a helmet allowing patients to move naturally whilst being scanned, has been developed by researchers at the Sir Peter Mansfield Imaging Centre, University of Nottingham and the Wellcome Centre for Human Neuroimaging, UCL. It is part of a five-year Wellcome funded project which has the potential to revolutionize the world of human brain imaging.
- Source: Medical Xpress
- 582
- March 22, 2018
brain medtech Researches
New AI technique dramatically improves the quality of medical imaging

AUTOMAP offers a number of potential benefits for clinical care, even beyond producing high-quality images in less time with MRI or with lower doses with X-ray, CT and PET. Because of its processing speed, the technique could help in making real-time decisions about imaging protocols while the patient is in the scanner.
- Source: Artificial Intelligence Research
- 515
- March 22, 2018
AI imaging machine learning Researches
Forbion Leads $19 Million Series B Financing of Escalier Biosciences to Advance its Topical and Systemic RORt Therapies for Psoriasis and other Autoimmune Diseases

Forbion, one of the leading European life science venture capital firms, today announced that it led the $19 million Series B financing of Escalier Biosciences BV, a privately held biopharmaceutical company based in Nijmegen, The Netherlands. Escalier Biosciences is developing both oral and topical ROR?t drug candidates for psoriasis and other autoimmune diseases.
- Source: biotech-365
- 809
- March 21, 2018
autoimmune Company Insight financing psoriasis
Dova Pharmaceuticals Signs Exclusive Distribution Agreement with Fosun Pharma For Mainland China and Hong Kong

Dova Pharmaceuticals, Inc. (DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, entered into an agreement through its wholly owned subsidiary, AkaRx, Inc., granting Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., (Fosun Pharma Industrial), a wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) (SHA:600196) (HKG:02196), the exclusive development and distribution rights of avatrombopag in mainland China and Hong Kong.
- Source: finance.yahoo
- 671
- March 21, 2018
avatrombopag Company Insight rare diseases
Insilico Medicine to launch R&D center and announce new research results in Taiwan ROC

Tuesday, March 20th, 2018, Insilico Medicine, a Baltimore-based artificial intelligence company specializing in drug discovery, biomarker development and aging research announced the launch of Insilico Taiwan, a subsidiary focusing on the development and validation of generative adversarial networks(GANs) and reinforcement learning for medicinal chemistry applications.
- Source: EurekAlert
- 615
- March 21, 2018
AI biomarker Company Insight Researches
UNITY Biotechnology, Inc. Completes $55 Million Series C Financing

UNITY Biotechnology, Inc. ("UNITY"), a privately held biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, announced the closing of a $55 million Series C financing.
- Source: prnewswire
- 724
- March 21, 2018
aging Market Views Series
DocDoc raises US$5.45mil in Series B funding round

Singapore-based DocDoc, an Asian patient empowerment company, announced on March 19 that it has raised US$5.45 million (RM21.33 million) in their Series B round of funding.
- Source: Digital News Asia
- 640
- March 21, 2018
AI Company Insight healthcare
Ionis Pharmaceuticals Partners With Akcea Therapeutics in a Potential $1.7 Billion Deal

In 2017, GlaxoSmithKline ended its partnership with Ionis Pharmaceuticals, Inc. to develop and market inotersen and a follow-up drug for rare diseases. After reviewing its options, Ionis has signed a worldwide license deal to Akcea Therapeutics for inotersen and AKCEA-TTR-LRx in a deal that could hit $1.7 billion. What makes this deal a bit unusual is that Akcea is a subsidiary of Ionis.
- Source: pharmalive
- 587
- March 20, 2018
Akcea-TTR-LRx GlaxoSmithKline Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.